[
  {
    "ts": null,
    "headline": "BridgeBio: Next Chapter Begins After Attruby Approval",
    "summary": "BridgeBio's Attruby (acoramidis) FDA approval for ATTR-CM treatment triggers $500M payment, positioning it to compete with Pfizer and Alnylam.",
    "url": "https://finnhub.io/api/news?id=ae91aa86a973d6c9462fa51a3ab594779e212773a1cb312dce83868f06613020",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732463295,
      "headline": "BridgeBio: Next Chapter Begins After Attruby Approval",
      "id": 131619037,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1225058423/image_1225058423.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "BridgeBio's Attruby (acoramidis) FDA approval for ATTR-CM treatment triggers $500M payment, positioning it to compete with Pfizer and Alnylam.",
      "url": "https://finnhub.io/api/news?id=ae91aa86a973d6c9462fa51a3ab594779e212773a1cb312dce83868f06613020"
    }
  }
]